Congestive heart failure and treatment in thalassemia major

Hemoglobin

Volumn 32, Issue 1-2, 2008, Pages 63-73

  Aessopos, Athanassios ^a   Kati, Maria ^a   Tsironi, Maria ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Department of Internal Medicine   (Greece)

Author keywords

Thalassemia (thal); Chelation; Congestive heart failure (CHF); Heart failure; Transfusion

Indexed keywords

ALFACALCIDOL; AMIODARONE; CALCIUM; CAPTOPRIL; CARVEDILOL; DEFERIPRONE; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FUROSEMIDE; HUMAN ALBUMIN; LOOP DIURETIC AGENT; SILDENAFIL; SPIRONOLACTONE;

CONFERENCE PAPER; CONGESTIVE HEART FAILURE; ENDOCRINE DISEASE; FOLLOW UP; HEART ARRHYTHMIA; HEART INJURY; HUMAN; HYPOALBUMINEMIA; KIDNEY DISEASE; KNOWLEDGE; LOADING DRUG DOSE; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; SINUS TACHYCARDIA; THALASSEMIA MAJOR;

ANIMALS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CARDIOMYOPATHIES; DIURETICS; ECHOCARDIOGRAPHY; HEART; HEART FAILURE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD;

EID: 39349092542     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701680839     Document Type: Conference Paper

References (41)

1. Weatherall DJ, Clegg JB. Inherited hemoglobin disorders: an increasing global health problem. Bull World Health Org 2001; 79(8):704-712.
2. Olivieri NF. The β-thalassemias. N Engl J Med 1999; 341(2):99-109.
3. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99(1):36-43.
4. 2) β-thalassemia intermedia in Greece. Pediatr Hematol Oncol 1995; 12(1):37-45.
5. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995; 80(1):58-68.
6. Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann NY Acad Sci 1998; 850:325-333.
7. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Cooleycare Programme. Lancet 1991; 337(8736):277-280.
8. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220):2051-2052.
9. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 2004; 104(1):34-39.
10. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89(10):1187-1193.
11. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104(1):263-269.
12. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30(2):219-227.
13. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004; 73(5):359-366.
14. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, Peters TJ. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14(12):719-724.
15. Barosi G, Arbustini E, Gavazzi A, Grasso M, Pucci A. Myocardial iron grading by endomyocardial biopsy. Eur J Hematol 1989; 42(4):382-388.
16. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005; 106(9):3242-3250.
17. Westwood MA, Sheppard MN, Awogbade M, Ellis G, Stephens AD, Pennell DJ. Myocardial biopsy and T2* magnetic resonance in heart failure due to thalassaemia. Br J Haematol 2005; 128(1):2.
18. Kyriacou K, Michaelides Y, Senkus R, Simamonian K, Pavlides N, Antoniades L, Zambartas C. Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultrastruct Pathol 2000; 24(2):75-81.
19. Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC. Right ventricular cardiomyopathy in β-thalassemia major. Eur Heart J 2002; 23(2):147-156.
20. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006; 23(5):662-668.
21. Forni GL, Derchi G. Typical manifestation of acute congestive heart failure in patients with thalassaemia major causing diagnostic delay in the emergency room. Eur J Heart Fail 2003; 5(5):607-608.
22. Borer JS, Henry WL, Epstein SE. Echocardiographic observations in patients with systemic infiltrative disease involving the heart. Am J Cardiol 1977; 39(2):184-188.
23. Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in β-thalassemia major. Circulation 1993; 88(3):1127-1135.
24. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23):2171-2179.
25. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006; 6(4):226-233.
26. Sermsappasuk P, Baek M, Weiss M. Kinetic analysis of myocardial uptake and negative inotropic effect of amiodarone in rat heart. Eur J Pharm Sci 2006; 28(3):243-248.
27. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91(9):1159-1161.
28. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 2006; 36(1):21-25.
29. Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypocalcemic heart failure in thalassemic patients. Int J Hematol 2006; 83(4):314-317.
30. Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 2002; 100(4):1516-1517.
31. Derchi G, Forni GL, Formisano F, Cappellini MD, Galanello R, D'Ascola G, Bina P, Magnano C, Lamagna M. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005; 90(4):452-458.
32. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350(9):886-895.
33. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005; 74(1):84-85.
34. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107(9):738-744.
35. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in β thalassemia patients receiving regular transfusion and iron chelation; reversal by intensified chelation. Acta Haematol 1990; 84(3):113-117.
36. Mourad HF, Hoffbrand VA, Sheikh-Taha M, Koussa S, Khoriaty IA, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients. Br J Haematol 2003; 121(1):187-189.
37. Kontoghiorges JG, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000; 23(3):211-223.
38. Wood JC, Tyszka M, Carson S, Nelson M, Coates T. Myocardial iron loading in transfusion dependent thalassemia and sickle-cell disease. Blood 2004; 103(5):1934-1936.
39. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2006; 107(9):3733-3737.
40. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332):516-520.
41. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91(7):873-880.